Zobrazeno 1 - 10
of 225
pro vyhledávání: '"Suayib, Yalcin"'
Autor:
Fatih Kus MD, Deniz Can Guven PhD, Hasan Cagri Yildirim PhD, Baran Akagunduz PhD, Serdar Karakaya PhD, Osman Sutcuoglu PhD, Elvin Chalabiyev MD, Arif Akyildiz MD, Baris Koksal MD, Yigit Berk Sahin MD, Ece Karaca MD, Oguz Alp Kavruk MD, Nefise Tugce Zor MD, Firat Sirvan MD, Ozan Yazici PhD, Suayib Yalcin PhD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Aims: This study aimed to assess the habits and knowledge of cancer patients regarding the use of herbal medicines and dietary supplements in cancer patients receiving immune checkpoint inhibitors (ICI). Methods: The data of 181 cancer patients who w
Externí odkaz:
https://doaj.org/article/171b5c2135e74f2db40143086b69d588
Autor:
Hasan Cagri Yildirim, Fatih Kus, Deniz Can Guven, Ece Karaca, Yunus Kaygusuz, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 170-176 (2023)
Introduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers to identify patients who may
Externí odkaz:
https://doaj.org/article/67323cc7fe9e425d97196951b9a3b644
Autor:
Deniz Can Guven, Taha Koray Sahin, Enes Erul, Alessandro Rizzo, Angela Dalia Ricci, Sercan Aksoy, Suayib Yalcin
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available da
Externí odkaz:
https://doaj.org/article/3ae9093ba7964ef68f6b39871f995827
Autor:
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Raffaele De Luca, Deniz Can Guven, Suayib Yalcin, Giovanni Brandi
Publikováno v:
Translational Oncology, Vol 25, Iss , Pp 101514- (2022)
Systemic treatments (e.g., chemotherapy and targeted therapies) have limited efficacy for patients with locally advanced – unresectable – and metastatic cholangiocarcinoma (CCA), with an overall survival of less than a year. Tumor microenvironmen
Externí odkaz:
https://doaj.org/article/5100a02873d64aa1bc6cba5336784642
Autor:
Michelle A. Mollica, Deborah K. Mayer, Kevin C. Oeffinger, Youngmee Kim, Susan S. Buckenmaier, Sudha Sivaram, Catherine Muha, Nur Aishah Taib, Elisabeth Andritsch, Chioma C. Asuzu, Ovidiu V. Bochis, Sheila Diaz, Maria Die Trill, Patricia J. Garcia, Luigi Grassi, Yosuke Uchitomi, Asim Jamal Shaikh, Michael Jefford, Hyun Jeong Lee, Christoffer Johansen, Emmanuel Luyirika, Elizabeth Jane Maher, Maria Madeline B. Mallillin, Theoneste Maniragaba, Anja Mehnert-Theuerkauf, C. S. Pramesh, Sabine Siesling, Orit Spira, Jonathan Sussman, Lili Tang, Nguyen V. Hai, Suayib Yalcin, Paul B. Jacobsen
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1394-1411 (2020)
PURPOSEThe purpose of this study was to describe follow-up care for breast and colorectal cancer survivors in countries with varying levels of resources and highlight challenges regarding posttreatment survivorship care.METHODSWe surveyed one key sta
Externí odkaz:
https://doaj.org/article/c2c20f3f9f3a44f896200450167e13e1
Autor:
Suayib Yalcin, Faysal Dane, Berna Oksuzoglu, Nuriye Yildirim Ozdemir, Abdurrahman Isikdogan, Metin Ozkan, Guzin Gonullu Demirag, Hasan Senol Coskun, Bulent Karabulut, Turkkan Evrensel, Mehmet Ali Ustaoglu, Feyyaz Ozdemir, Hande Turna, Tugba Yavuzsen, Faruk Aykan, Alper Sevinc, Hakan Akbulut, Deniz Yuce, Mutlu Hayran, Saadettin Kilickap
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in a
Externí odkaz:
https://doaj.org/article/1ae3c043ebb54a6c82250c0cb4ea7be9
Autor:
Georgios N. Tsaousis, Eirini Papadopoulou, Angela Apessos, Konstantinos Agiannitopoulos, Georgia Pepe, Stavroula Kampouri, Nikolaos Diamantopoulos, Theofanis Floros, Rodoniki Iosifidou, Ourania Katopodi, Anna Koumarianou, Christos Markopoulos, Konstantinos Papazisis, Vasileios Venizelos, Ioannis Xanthakis, Grigorios Xepapadakis, Eugeniu Banu, Dan Tudor Eniu, Serban Negru, Dana Lucia Stanculeanu, Andrei Ungureanu, Vahit Ozmen, Sualp Tansan, Mehmet Tekinel, Suayib Yalcin, George Nasioulas
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-19 (2019)
Abstract Background Hereditary cancer predisposition syndromes are responsible for approximately 5–10% of all diagnosed cancer cases. In the past, single-gene analysis of specific high risk genes was used for the determination of the genetic cause
Externí odkaz:
https://doaj.org/article/dc43f140d22c4f09805d95f871555460
Autor:
Deniz Can Guven, Hasan Cagri Yildirim, Elvin Chalabiyev, Fatih Kus, Feride Yilmaz, Serkan Yasar, Arif Akyildiz, Burak Yasin Aktas, Suayib Yalcin, Omer Dizdar
Publikováno v:
Expert Review of Anticancer Therapy. 23:243-256
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e593a57d28a53b432f8f1f51eab9f515
https://doi.org/10.1080/14737140.2023.2183844
https://doi.org/10.1080/14737140.2023.2183844
Autor:
Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mustafa Arici
Publikováno v:
Anti-Cancer Drugs. 34:783-790
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81b81d900815a5a654457235dfca5f5a
https://doi.org/10.1097/cad.0000000000001463
https://doi.org/10.1097/cad.0000000000001463
Autor:
Sahin Lacin MD, Suayib Yalcin MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 19 (2020)
Background: Neovascularization plays a crucial pathogenic role in tumor development and vascular endothelial growth factor (VEGF-A) is a key signaling element that drives angiogenesis, thereby facilitating hepatocellular cancer (HCC) growth and metas
Externí odkaz:
https://doaj.org/article/f611211756ae4b208fd6990109df7fdd